Antje van der Zee-Neuen1, Polina Putrik1, Sofia Ramiro2, Andras Keszei3, Rob de Bie1, Astrid Chorus4, Annelies Boonen1. 1. Maastricht University, CAPHRI, Maastricht, The Netherlands. 2. Amsterdam Rheumatology Center, University of Amsterdam, Amsterdam, The Netherlands, and Hospital Garcia de Orta, Almada, Portugal. 3. Aachen University, Aachen, Germany. 4. The Netherlands Organization for Applied Scientific Research, Leiden, The Netherlands.
Abstract
OBJECTIVE: Chronic diseases are increasingly prevalent and often occur as multimorbidity. This study compares the impact of musculoskeletal disorders (MSKDs) on health and health care costs with other chronic diseases, and assesses the additional impact of MSKDs on these outcomes when occurring as part of multimorbidity. METHODS: A household survey in a random Dutch population sample (n = 8,904) yielded information on sociodemographics, presence of 9 physician-confirmed chronic diseases (i.e., musculoskeletal, migraine, diabetes mellitus, cardiovascular, cancer, respiratory, skin, mental, and gastrointestinal), physical component summary (PCS) and mental component summary (MCS) scores of the Short Form 12 health survey, and health care utilization. The independent influence of different diseases and the role of MSKDs with increasing number of morbidities on PCS/MCS and 3-month societal health care costs were explored through multivariable linear and zero-inflated negative binomial regressions, respectively. RESULTS: Twenty percent of all subjects and 56% of those with multimorbidity had an MSKD. MSKDs had the largest impact on PCS (β = -8.37 [95% confidence interval (95% CI) -8.84, -7.89]) but no significant impact on MCS. When MSKDs occurred as part of multimorbidity, an amplification of the adverse effect on PCS but not on MCS was seen, irrespective of the number of comorbidities. MSKDs were responsible for a 2-fold increase in costs (Exp [β] = 2.27 [95% CI 2.08, 2.51]), which was the second highest cost increase of all diseases (after cancer). Significant amplification of costs was seen when MSKDs co-occurred with mental diseases. CONCLUSION: MSKDs often co-occur with other chronic diseases. In the context of multimorbidity, presence of an MSKD amplifies the impact on physical health, and to a lesser extent on health care costs, but not on mental health.
OBJECTIVE:Chronic diseases are increasingly prevalent and often occur as multimorbidity. This study compares the impact of musculoskeletal disorders (MSKDs) on health and health care costs with other chronic diseases, and assesses the additional impact of MSKDs on these outcomes when occurring as part of multimorbidity. METHODS: A household survey in a random Dutch population sample (n = 8,904) yielded information on sociodemographics, presence of 9 physician-confirmed chronic diseases (i.e., musculoskeletal, migraine, diabetes mellitus, cardiovascular, cancer, respiratory, skin, mental, and gastrointestinal), physical component summary (PCS) and mental component summary (MCS) scores of the Short Form 12 health survey, and health care utilization. The independent influence of different diseases and the role of MSKDs with increasing number of morbidities on PCS/MCS and 3-month societal health care costs were explored through multivariable linear and zero-inflated negative binomial regressions, respectively. RESULTS: Twenty percent of all subjects and 56% of those with multimorbidity had an MSKD. MSKDs had the largest impact on PCS (β = -8.37 [95% confidence interval (95% CI) -8.84, -7.89]) but no significant impact on MCS. When MSKDs occurred as part of multimorbidity, an amplification of the adverse effect on PCS but not on MCS was seen, irrespective of the number of comorbidities. MSKDs were responsible for a 2-fold increase in costs (Exp [β] = 2.27 [95% CI 2.08, 2.51]), which was the second highest cost increase of all diseases (after cancer). Significant amplification of costs was seen when MSKDs co-occurred with mental diseases. CONCLUSION: MSKDs often co-occur with other chronic diseases. In the context of multimorbidity, presence of an MSKD amplifies the impact on physical health, and to a lesser extent on health care costs, but not on mental health.
Authors: Nigel P Stocks; David A González-Chica; Robyn L Woods; Jessica E Lockery; Rory S J Wolfe; Anne M Murray; Brenda Kirpach; Raj C Shah; Mark R Nelson; Christopher M Reid; Michael E Ernst; John J McNeil Journal: Qual Life Res Date: 2018-11-08 Impact factor: 4.147
Authors: Carol A Hitchon; Randy Walld; Christine A Peschken; Charles N Bernstein; James M Bolton; Renée El-Gabalawy; John D Fisk; Alan Katz; Lisa M Lix; James Marriott; Scott B Patten; Jitender Sareen; Alexander Singer; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: David Alejandro González-Chica; Catherine L Hill; Tiffany K Gill; Phillipa Hay; Dandara Haag; Nigel Stocks Journal: Health Qual Life Outcomes Date: 2017-12-21 Impact factor: 3.186
Authors: Carmen Stolwijk; Ivette Essers; Filip van den Bosch; Maxime Dougados; Adrien Etcheto; Désirée van der Heijde; Robert Landewé; Anna Molto; Astrid van Tubergen; Annelies Boonen Journal: Rheumatology (Oxford) Date: 2020-07-01 Impact factor: 7.580
Authors: Amanda Williams; Steven J Kamper; John H Wiggers; Kate M O'Brien; Hopin Lee; Luke Wolfenden; Sze Lin Yoong; Emma Robson; James H McAuley; Jan Hartvigsen; Christopher M Williams Journal: BMC Med Date: 2018-09-25 Impact factor: 8.775